Pridopidine for the treatment of mitochondrial-associated diseases and disorders and endoplasmic reticulum (ER) stress
The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
1 . A method of treating, suppressing, or inhibiting mitochondrial myopathy in a subject by administering to the subject pridopidine or a pharmaceutically acceptable salt thereof, and the mitochondrial myopathy is selected from the group consisting of Mitochondrial DNA depletion syndrome (MDS), Neuropathy, Wolfram Syndrome, Chronic Progressive External Ophthalmoplegia (C/PEO), Dominant Optical Atrophy (DOA), or a combination thereof, and wherein the Neuropathy is not Optic neuropathy.
2 . The method of claim 1 , wherein said pridopidine is in its neutral/base form or a pharmaceutically acceptable salt form.
3 . The method of claim 1 , wherein said pridopidine is pridopidine hydrochloride.
4 . The method of claim 1 , wherein said composition is administered in the form of an inhalable powder, an injectable, a liquid, a gel, a solid, a capsule, eye drops or a tablet.
5 . The method of claim 1 , wherein said composition is administered in a multiparticulate delivery vehicle comprising pellets, beads, granules, microparticles, nanoparticles, or a combination thereof.
6 . The method of claim 1 , wherein said composition is administered once, twice, or three times a day.